About: COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy
Creator	Perricone, Carlo Shoenfeld, Yehuda Bartoloni, Elena Bursi, Roberto Cafaro, Giacomo Gerli, Roberto Guidelli, Giacomo
Source	Medline; PMC
abstract	SARS-CoV-2 infection is characterized by a protean clinical picture that can range from asymptomatic patients to life-threatening conditions. Severe COVID-19 patients often display a severe pulmonary involvement and develop neutrophilia, lymphopenia, and strikingly elevated levels of IL-6. There is an over-exuberant cytokine release with hyperferritinemia leading to the idea that COVID-19 is part of the hyperferritinemic syndrome spectrum. Indeed, very high levels of ferritin can occur in other diseases including hemophagocytic lymphohistiocytosis, macrophage activation syndrome, adult-onset Still’s disease, catastrophic antiphospholipid syndrome and septic shock. Numerous studies have demonstrated the immunomodulatory effects of ferritin and its association with mortality and sustained inflammatory process. High levels of free iron are harmful in tissues, especially through the redox damage that can lead to fibrosis. Iron chelation represents a pillar in the treatment of iron overload. In addition, it was proven to have an anti-viral and anti-fibrotic activity. Herein, we analyse the pathogenic role of ferritin and iron during SARS-CoV-2 infection and propose iron depletion therapy as a novel therapeutic approach in the COVID-19 pandemic.
has issue date	2020-07-17(xsd:dateTime)
bibo:doi	10.1007/s12026-020-09145-5
bibo:pmid	32681497
has license	cc-by
sha1sum (hex)	0017447a237cee0445a83538a538e7c6e9336de6
schema:url	https://doi.org/10.1007/s12026-020-09145-5
resource representing a document's title	COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy
has PubMed Central identifier	PMC7366458
has PubMed identifier	32681497
schema:publication	Immunol Res
resource representing a document's body	covid:0017447a237cee0445a83538a538e7c6e9336de6#body_text
is schema:about of	named entity 'fibrosis' named entity 'overload' named entity 'NEUTROPHILIA' named entity 'ACTIVITY' named entity 'ITS' named entity 'SEVERE COVID-19' named entity '27S' named entity 'ASSOCIATION' named entity 'LIFE' named entity 'OF FREE' named entity 'CYTOKINE RELEASE' named entity 'ASYMPTOMATIC' named entity 'IRON CHELATION' named entity 'HYPERFERRITINEMIA' named entity 'NUMEROUS' named entity 'PATHOGENIC' named entity 'ELEVATED' named entity 'DAMAGE' named entity 'DISEASES' named entity 'immunomodulatory' named entity 'iron' named entity 'release' named entity 'High' named entity 'represents' named entity 'cytokine' named entity 'iron' named entity 'therapy' named entity 'infection' named entity 'COVID' named entity 'lymphopenia' named entity 'anti-fibrotic' named entity 'adult-onset Still's disease' named entity 'COVID-19' named entity 'neutrophilia' named entity 'fibrosis' named entity 'COVID-19' named entity 'inflammatory process' named entity 'chelate' named entity 'lipids' named entity 'infection' named entity 'sepsis' named entity 'Iron chelation' named entity 'hepatitis B virus' named entity 'NK cell' named entity 'influenza A virus' named entity 'ferritin' named entity 'diagnostic criteria' named entity 'oxygen radicals' named entity 'adenovirus' named entity 'regulates expression' named entity 'iron bound' named entity 'IFN' named entity 'EBV' named entity 'clinical practice' named entity 'fibrosis' named entity 'ferritin' named entity 'deferiprone' named entity 'ICU' named entity 'AOSD' named entity 'M2 macrophage' named entity 'neutrophils' named entity 'cytosolic' named entity 'cytokines' named entity 'interferon' named entity 'MAS' named entity 'septic shock' named entity 'iron chelation' named entity 'cytokine' named entity 'iron overload' named entity 'SLE' named entity 'high levels' named entity 'tissue factor' named entity 'macrophages' named entity 'chemokine receptor' named entity 'lupus anticoagulant'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software